Genprex Inc

GNPX

Company Profile

  • Business description

    Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company’s product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

  • Contact

    3300 Bee Cave Road
    Suite 650-227
    AustinTX78746
    USA

    T: +1 877 774-4679

    https://www.genprex.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    15

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,786.7013.100.15%
CAC 407,557.310.85-0.01%
DAX 4023,649.30150.970.64%
Dow JONES (US)43,386.84404.410.94%
FTSE 1008,735.6016.850.19%
HKSE24,357.2131.810.13%
NASDAQ20,167.91194.360.97%
Nikkei 22540,215.36630.781.59%
NZX 50 Index12,544.9164.860.52%
S&P 5006,141.0248.860.80%
S&P/ASX 2008,556.806.000.07%
SSE Composite Index3,443.624.83-0.14%

Market Movers